Xenon Pharmaceuticals Inc.

Genentech, Inc.

Jean-Christophe Andrez

Christoph Martin Dehnhardt

Thilo Focken

Michael Edward Grimwood

Alla Yurevna Zenova

Sultan Chowdhury

Qi Jia

Michael Scott Wilson

Shaoyi Sun

Brian Salvatore Safina

Ivan William Hemeon

Kristen Nicole Burford

Paul Robert Bichler

Robert Joseph Devita

Philippe Bergeron

Shannon Marie Decker

Abid Hasan

Wei Gong

Syed Abid Hasan

James Philip Johnson, Jr

James Roy Empfield

Charles Jay Cohen

Daniel P Sutherlin

Daniel Fred Ortwine

Jun M Li

Steven Sigmund Wesolowski

Verner Alexander Lofstrand

Tao Sheng

Zhiguo Liu

Jiuxiang Zhu

Andrew D White

Chien-An Chen

David Earl Bogucki

James Philip Johnson

Jun Li

Jr Johnson James Philip

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Benzenesulfonamide compounds and their use as therapeutic agents

Benzenesulfonamide compouds and their use as therapeutic agents

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables R, R, subscript n, subscript q, ring A, X, L, subscript m, X, R, R, R, R, R, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Therapeutic compounds and methods of use thereof

This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

This invention is directed to methods of preparing benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables R, R, subscript n, subscript q, ring A, X, L, subscript m, X, R, R, R, R, R, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. 

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, subscript n, ring A, X, L, subscript m, X, R, R, R, R, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Substituted benzamides and methods of use thereof

The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables R, subscript n, ring A, X, L, subscript m, X, B, R, R, R, R, Rand Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

N-substituted benzamides and methods of use thereof

Growing community of inventors

Burnaby, Canada

Jean-Christophe Andrez